CNSDose
Commercial- Indications
- Depression
Company intelligence / Profile preview
Incite Genomics/Incite Health offers commercial pharmacogenomic testing services focused on mental health medication optimization. Their CNSDose platform is being clinically validated in an 800-patient trial for severe depression at the University of Melbourne. The company’s reports are based on CPIC guidelines and aim to reduce adverse drug reactions by personalizing psychiatric medication selection using genetic data.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Incite Genomics.